Filing Details

Accession Number:
0001209191-20-058807
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-17 17:19:12
Reporting Period:
2020-11-13
Accepted Time:
2020-11-17 17:19:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
19411 Magellan Health Inc MGLN Services-Hospitals (8060) 581076937
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1647234 Mostafa Kamal 4801 East Washington Street
Phoenix AZ 85034
Ceo, Magellan Rx Management No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Common Stock, $0.01 Par Value Acquisiton 2020-11-13 13,282 $68.50 18,899 No 4 X Direct
Ordinary Common Stock, $0.01 Par Value Disposition 2020-11-13 13,282 $83.82 5,617 No 4 S Direct
Ordinary Common Stock, $0.01 Par Value Acquisiton 2020-11-16 7,603 $66.57 13,220 No 4 X Direct
Ordinary Common Stock, $0.01 Par Value Disposition 2020-11-16 7,603 $86.57 5,617 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 X Direct
No 4 S Direct
No 4 X Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2020-11-13 13,282 $0.00 13,282 $68.50
Common Stock Stock Option (right to buy) Disposition 2020-11-16 7,603 $0.00 7,603 $66.57
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2027-03-03 No 4 X Direct
27,205 2029-03-05 No 4 X Direct
Footnotes
  1. This transaction was effectuated pursuant to a Rule 10b-5-1 Plan.
  2. The number of securities reported represents an aggregate number of shares sold in multiple open market transactions at an average price of $83.8216. The price reported represents the weighted average price. The Reporting Person undertakes to provide staff of the SEC, the issuer, or a stockholder of the issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
  3. All of the stock options in this tranche have vested in full.
  4. Not applicable.
  5. The remainder of 27,205 options shall vest in equal increments on March 3, 2021 and 2022.